Atea Pharmaceuticals (AVIR) Change in Account Payables (2019 - 2026)

Atea Pharmaceuticals' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 219.46% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 114.97% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, up 4019.9% from the prior year.
• Change in Account Payables declined to -$3.5 million in Q1 2026 per AVIR's latest filing, from $9.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $16.9 million in Q1 2024 and bottomed at -$15.7 million in Q2 2024.
• The 5-year median for Change in Account Payables is $315000.0 (2024), against an average of $288941.2.
• Across the five-year window, Change in Account Payables soared 1012.21% in 2024 and plunged 1791.75% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $1.4 million in 2022, then jumped by 169.16% to $3.9 million in 2023, then tumbled by 134.4% to -$1.3 million in 2024, then jumped by 810.63% to $9.4 million in 2025, then plunged by 137.1% to -$3.5 million in 2026.
• Per Business Quant, the three latest AVIR Change in Account Payables figures stand at -$3.5 million (Q1 2026), $9.4 million (Q4 2025), and -$5.3 million (Q3 2025).